Literature DB >> 6118060

Labetalol therapy in patients with systemic hypertension and angina pectoris: effects of combined alpha and beta adrenoceptor blockade.

W H Frishman, J A Strom, M Kirschner, M Poland, N Klein, S Halprin, T H LeJemtel, M Kram, E H Sonnenblick.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6118060     DOI: 10.1016/0002-9149(81)90359-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


× No keyword cloud information.
  12 in total

Review 1.  Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.

Authors:  W H Frishman
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

2.  Labetolol in patients with hypertension and varying degrees of renal impairment.

Authors:  E G Breen; M Lombard; A Watson; J A Keogh
Journal:  Ir J Med Sci       Date:  1984-10       Impact factor: 1.568

3.  Magnitude and mechanisms of the antihypertensive action of labetalol, including ambulatory assessment.

Authors:  G R Bellamy; S N Hunyor; D Roffe; J Massang
Journal:  Br J Clin Pharmacol       Date:  1983-07       Impact factor: 4.335

4.  Soft drugs. XX. Design, synthesis, and evaluation of ultra-short acting beta-blockers.

Authors:  H S Yang; W M Wu; N Bodor
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

Review 5.  Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.

Authors:  K L Goa; P Benfield; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

6.  Comparison of medroxalol and labetalol, drugs with combined alpha- and beta-adrenoceptor antagonist properties.

Authors:  H L Elliott; K McLean; P A Meredith; D J Sumner; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1984-05       Impact factor: 4.335

Review 7.  Alpha- and beta-blockade in angina pectoris.

Authors:  S H Taylor
Journal:  Drugs       Date:  1984       Impact factor: 9.546

Review 8.  Role of vasodilation in the antihypertensive and antianginal effects of labetalol: implications for therapy of combined hypertension and angina.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

Review 9.  Labetalol in normotensive patients with angina pectoris.

Authors:  K Fox; A A Quyyumi
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

10.  Systemic and coronary hemodynamics of labetalol in normotensive patients with ischemic heart disease.

Authors:  R L Feldman; X E Prida; C R Lambert; J A Hill
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.